| Revision as of 12:53, 15 February 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 472909507 of page Dornase_alfa for the Chem/Drugbox validation project (updated: 'UNII'). |
Latest revision as of 00:23, 8 January 2024 edit Entranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers173,103 edits Importing Wikidata short description: "Pharmaceutical drug"Tag: Shortdesc helper |
| Line 1: |
Line 1: |
|
|
{{Short description|Pharmaceutical drug}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
|
{{Medref|date=February 2022}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 461091235 |
|
| verifiedrevid = 476997032 |
|
| IUPAC_name = |
|
|
| image = |
|
| IUPAC_name = |
|
|
| image = |
| ⚫ |
| drug_name = Dornase Alfa |
|
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = Pulmozyme |
|
| tradename = Pulmozyme |
|
| Drugs.com = {{drugs.com|monograph|dornase_alfa}} |
|
| Drugs.com = {{drugs.com|monograph|dornase_alfa}} |
|
| MedlinePlus = a694002 |
|
| MedlinePlus = a694002 |
|
⚫ |
| DailyMedID = Dornase alfa |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
|
|
| pregnancy_AU = B1 |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
|
|
| pregnancy_AU_comment = <ref name="Pulmozyme PI" /> |
|
| pregnancy_category = B |
|
| pregnancy_category = |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
|
⚫ |
| routes_of_administration = ] |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
|
|
| ATC_prefix = R05 |
|
⚫ |
| ATC_suffix = CB13 |
|
|
|
|
|
| legal_AU = S4 |
|
|
| legal_AU_comment = <ref name="Pulmozyme PI"> guildlink.com.au</ref> |
|
|
| legal_CA = Rx-only |
|
|
| legal_CA_comment = / Schedule D<ref>{{cite web | title=Pulmozyme Product information | website=] | date=25 April 2012 | url=https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=15483 | access-date=9 January 2023}}</ref> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_US = Rx-only |
|
|
| legal_US_comment = <ref name="Pulmozyme FDA label">{{cite web | title=Pulmozyme- dornase alfa solution | website=DailyMed | date=21 October 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8c78a7e-ff99-48f3-8952-643ec2ea0f86 | access-date=9 January 2023}}</ref> |
|
| legal_status = |
|
| legal_status = Rx-only |
| ⚫ |
| routes_of_administration = inhalation |
|
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!-- Pharmacokinetic data --> |
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
<!-- Identifiers --> |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|changed|CAS}} |
|
| CAS_number = 9003-98-9 |
|
| CAS_number = 143831-71-4 |
|
| ATC_prefix = R05 |
|
| PubChem = |
| ⚫ |
| ATC_suffix = CB13 |
|
|
| PubChem = |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = DB00003 |
|
| DrugBank = DB00003 |
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
⚫ |
| ChemSpiderID = none |
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
| UNII = <!-- blanked - oldvalue: 953A26OA1Y --> |
|
| UNII = 953A26OA1Y |
|
|
| KEGG = D03896 |
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ⚫ |
| ChemSpiderID = NA |
|
|
|
|
|
|
<!--Chemical data--> |
|
<!-- Chemical data --> |
|
|
| C=1321 | H=1999 | N=339 | O=396 | S=9 |
|
| chemical_formula = |
|
|
| molecular_weight = |
|
|
}} |
|
}} |
|
|
|
|
|
'''Dornase alfa''', sold under the brand name '''Pulmozyme''', is used for the treatment of ].<ref name="Pulmozyme FDA label" /> It is a recombinant human ] (rhDNase), an ] which selectively cleaves ].<ref name="Pulmozyme FDA label" /> Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces ] in the lungs, promoting improved clearance of secretions.<ref name="Pulmozyme FDA label" /> It is produced in ] cells.<ref name="Pulmozyme FDA label" /> |
|
|
|
|
|
== Medical uses == |
|
|
Dornase alfa is ] for the management of people with cystic fibrosis to improve pulmonary function.<ref name="Pulmozyme FDA label" /> |
|
|
|
|
|
== Society and culture == |
|
|
=== Legal status === |
|
|
Dornase alfa is an ].<ref>{{cite journal|last=Collier|first=Joe|title=Dornase-alfa and orphan drugs|journal=The Lancet|date=1 September 1995|volume=346|issue=8975|pages=633|doi=10.1016/S0140-6736(95)91460-9|pmid=7651014|s2cid=5456247}}</ref> |
|
|
|
|
|
== Research == |
|
|
Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants ].<ref name="pmid17436388">{{cite journal| vauthors=Erdeve O, Uras N, Atasay B, Arsan S| title=Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series. | journal=Croat Med J | year= 2007 | volume= 48 | issue= 2 | pages= 234–9 | pmid=17436388 | pmc=2080511 }}</ref><ref name="pmid16137347">{{cite journal| vauthors=Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ| title=DNase and atelectasis in non-cystic fibrosis pediatric patients. | journal=Crit Care | year= 2005 | volume= 9 | issue= 4 | pages= R351-6 | pmid=16137347 | doi=10.1186/cc3544 | pmc=1269442 | doi-access=free }}</ref> |
|
|
|
|
|
== References == |
|
|
{{Reflist}} |
|
|
|
|
|
{{Cough and cold preparations}} |
|
|
{{Portal bar | Medicine}} |
|
|
|
|
|
{{DEFAULTSORT:Dornase Alfa}} |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
|
|
|
] |